Tummers Quirijn R J G, Hoogstins Charlotte E S, Gaarenstroom Katja N, de Kroon Cor D, van Poelgeest Mariette I E, Vuyk Jaap, Bosse Tjalling, Smit Vincent T H B M, van de Velde Cornelis J H, Cohen Adam F, Low Philip S, Burggraaf Jacobus, Vahrmeijer Alexander L
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Centre for Human Drug Research, Leiden, The Netherlands.
Oncotarget. 2016 May 31;7(22):32144-55. doi: 10.18632/oncotarget.8282.
Intraoperative fluorescence imaging of the folate-receptor alpha (FRα) could support completeness of resection in cancer surgery. Feasibility of EC17, a FRα-targeting agent that fluoresces at 500nm, was demonstrated in a limited series of ovarian cancer patients. Our objective was to evaluate EC17 in a larger group of ovarian cancer patients. In addition, we assessed the feasibility of EC17 in patients with breast cancer.
Two-to-three hours before surgery 0.1mg/kg EC17 was intravenously administered to 12 patients undergoing surgery for ovarian cancer and to 3 patients undergoing surgery for biopsy-proven FRα-positive breast cancer. The number of lesions/positive margins detected with fluorescence and concordance between fluorescence and tumor- and FRα-status was assessed in addition to safety and pharmacokinetics.
Fluorescence imaging in ovarian cancer patients allowed detection of 57 lesions of which 44 (77%) appeared malignant on histopathology. Seven out of these 44 (16%) were not detected with inspection/palpation. Histopathology demonstrated concordance between fluorescence and FRα- and tumor status. Fluorescence imaging in breast cancer patients, allowed detection of tumor-specific fluorescence signal. At the 500nm wavelength, autofluorescence of normal breast tissue was present to such extent that it interfered with tumor identification.
FRα is a favorable target for fluorescence-guided surgery as EC17 produced a clear fluorescent signal in ovarian and breast cancer tissue. This resulted in resection of ovarian cancer lesions that were otherwise not detected. Notwithstanding, autofluorescence caused false-positive lesions in ovarian cancer and difficulty in discriminating breast cancer-specific fluorescence from background signal. Optimization of the 500nm fluorophore, will minimize autofluorescence and further improve intraoperative tumor detection.
术中对叶酸受体α(FRα)进行荧光成像有助于癌症手术中实现完整切除。在一小部分卵巢癌患者中已证明EC17(一种在500nm处发出荧光的FRα靶向剂)的可行性。我们的目标是在更大规模的卵巢癌患者群体中评估EC17。此外,我们还评估了EC17在乳腺癌患者中的可行性。
在手术前两到三小时,将0.1mg/kg的EC17静脉注射给12例接受卵巢癌手术的患者以及3例经活检证实为FRα阳性乳腺癌的手术患者。除了安全性和药代动力学外,还评估了通过荧光检测到的病变/阳性切缘数量以及荧光与肿瘤和FRα状态之间的一致性。
卵巢癌患者的荧光成像检测到57个病变,其中44个(77%)在组织病理学上显示为恶性。这44个病变中有7个(16%)通过检查/触诊未被发现。组织病理学显示荧光与FRα和肿瘤状态之间具有一致性。乳腺癌患者的荧光成像检测到肿瘤特异性荧光信号。在500nm波长下,正常乳腺组织的自发荧光程度足以干扰肿瘤识别。
由于EC17在卵巢癌和乳腺癌组织中产生清晰的荧光信号,FRα是荧光引导手术的理想靶点。这使得原本未被发现的卵巢癌病变得以切除。尽管如此,自发荧光在卵巢癌中导致假阳性病变,并且难以将乳腺癌特异性荧光与背景信号区分开来。优化500nm荧光团将最大限度减少自发荧光并进一步改善术中肿瘤检测。